Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...

Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...

Jushi Holdings Inc. ("Jushi” or the "Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis ...

Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...

研究内容：本文建立胰腺导管腺癌（PDAC）及其癌旁来源的类器官（PDO），并在PDO中评估溶瘤腺病毒（OA）的复制性、肿瘤选择性和敏感性。发现OA仅在来自PDAC的PDO中复制，并表现出良好的肿瘤选择性。同时，PDO模型对OA的敏感性表现出个体差异，且与OA在皮下异种 ...

Development of animal models for bone cancer faces another challenge in the accessibility of tumor engraftment sites. Here, we describe a protocol to develop an orthotopic humanized mouse model for a ...

Research Progress of c-Kit in Platinum-Resistant Ovarian Cancer. Journal of Biosciences and Medicines, 13, 404-412. doi: 10.4236/jbm.2025.132030 . According to the date from Chinese Center for Disease ...

The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models, a platform ...

Herein, hybrid cell membrane–biomimetic near-infrared II surface-enhanced Raman spectroscopy (NIR-II SERS) probes are reported for intraoperative resection guidance of orthotopic glioblastoma. A novel ...

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, P. R. China ...

Figure 2: The algorithm used for the screening of patients on the waiting list for orthotopic liver transplantation and the therapeutic decisions made thereafter. Although no peroperative deaths ...